pipobroman
Trade name: vercyte
Small moleculeapproved
Approved
Jul 1, 1966
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Alkylating agent
Approval history
- approvedPriority reviewJul 1, 1966
Chemistry & pharmacology
Loading structure…
SMILES
BrCCC(=O)N1CCN(CC1)C(=O)CCBr- Mol. weight
- 356.054 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPipobroman ↗
- NCATS6Q99RDT97R ↗
- ChEMBLCHEMBL2219740 ↗
- ChEMBLCHEMBL1585 ↗
Also known as
- a-8103
- a-8103
- amedel
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- pipobroman
- vercyte
- vercyte
- vercyte
- vercyte
- vercyte